AstraZeneca
AZN
1,222 hedge funds and large institutions have $34.7B invested in AstraZeneca in 2025 Q2 according to their latest regulatory filings, with 97 funds opening new positions, 459 increasing their positions, 438 reducing their positions, and 111 closing their positions.
130% more call options, than puts
Call options by funds: $596M | Put options by funds: $259M
5% more repeat investments, than reductions
Existing positions increased: 459 | Existing positions reduced: 438
2% less funds holding
Funds holding: 1,251 → 1,222 (-29)
7% less capital invested
Capital invested by funds: $37.3B → $34.7B (-$2.61B)
8.3% less ownership
Funds ownership: 16.3% → 8% (-8.3%)
13% less first-time investments, than exits
New positions opened: 97 | Existing positions closed: 111
50% less funds holding in top 10
Funds holding in top 10: 22 → 11 (-11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fayez Sarofim & Co
Houston,
Texas
|
+$166M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$137M |
| 3 |
Jennison Associates
New York
|
+$112M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$104M |
| 5 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$97.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$360M |
| 2 |
Morgan Stanley
New York
|
-$249M |
| 3 |
SFM
Soros Fund Management
New York
|
-$202M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$171M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$123M |
AZN Hedge Fund Activity: Q2 2025 in Review
1,222 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q2 2025, worth a combined $34.7B — down 7% from $37.3B a quarter earlier.
Sellers outnumbered buyers: 111 funds closed out of AZN and 97 opened new positions — a net loss of 14 holders — while 438 trimmed existing stakes and 459 added.
The largest buyer was Fayez Sarofim & Co, adding an estimated $166M. The largest seller was T. Rowe Price Associates, cutting an estimated $360M.
- 1,222 institutional investors held AstraZeneca (AZN) as of Q2 2025, down from 1,251 in Q1 2025.
- Funds reported $34.7B of AstraZeneca stock for Q2 2025, down 7% quarter-over-quarter.
- 97 funds opened new AstraZeneca positions in Q2 2025 and 111 closed out, a net change of -14 holders.
- The largest AstraZeneca buyer in Q2 2025 was Fayez Sarofim & Co, an estimated $166M added.
- The largest AstraZeneca seller in Q2 2025 was T. Rowe Price Associates, an estimated $360M sold.
Based on aggregated 13F filings for Q2 2025.